CY1122111T1 - Παραγωγα πολυκυκλικου αμιδιου ως cdk9 αναστολεις - Google Patents
Παραγωγα πολυκυκλικου αμιδιου ως cdk9 αναστολειςInfo
- Publication number
- CY1122111T1 CY1122111T1 CY20191100636T CY191100636T CY1122111T1 CY 1122111 T1 CY1122111 T1 CY 1122111T1 CY 20191100636 T CY20191100636 T CY 20191100636T CY 191100636 T CY191100636 T CY 191100636T CY 1122111 T1 CY1122111 T1 CY 1122111T1
- Authority
- CY
- Cyprus
- Prior art keywords
- cancer
- lymphoma
- treatment
- membered heterocycloalkyl
- amide derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Polyesters Or Polycarbonates (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Detergent Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562185852P | 2015-06-29 | 2015-06-29 | |
| PCT/EP2016/064899 WO2017001354A1 (en) | 2015-06-29 | 2016-06-27 | Polycyclic amide derivatives as cdk9 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1122111T1 true CY1122111T1 (el) | 2020-11-25 |
Family
ID=56292699
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100636T CY1122111T1 (el) | 2015-06-29 | 2019-06-19 | Παραγωγα πολυκυκλικου αμιδιου ως cdk9 αναστολεις |
| CY20211101125T CY1125066T1 (el) | 2015-06-29 | 2021-12-22 | Πολυκυκλικα αμιδικα παραγωγα ως αναστολεις cdk9 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211101125T CY1125066T1 (el) | 2015-06-29 | 2021-12-22 | Πολυκυκλικα αμιδικα παραγωγα ως αναστολεις cdk9 |
Country Status (38)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020003270A (es) | 2017-09-25 | 2020-07-20 | Astrazeneca Ab | Combinacion de un inhibidor de btk y un inhibidor de cdk9 para tratar el cancer. |
| US11319295B2 (en) | 2017-10-09 | 2022-05-03 | Merck Sharp & Dohme Corp. | Substituted phenyloxetane and phenyltetrahydrofuran compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors |
| CN108129288B (zh) * | 2017-12-27 | 2021-01-22 | 上海毕得医药科技股份有限公司 | 一种反式-3-羟基环丁基甲酸的合成方法 |
| TWI810397B (zh) | 2018-11-14 | 2023-08-01 | 瑞典商阿斯特捷利康公司 | 治療癌症之方法 |
| US20220267321A1 (en) * | 2019-06-27 | 2022-08-25 | Medshine Discovery Inc. | Azaindole pyrazole compounds as cdk9 inhibitors |
| WO2021050824A1 (en) * | 2019-09-11 | 2021-03-18 | Prelude Therapeutics Incorporated | Cdk inhibitors and their use as pharmaceuticals |
| JP2023505850A (ja) * | 2019-12-09 | 2023-02-13 | 石薬集団中奇制薬技術（石家庄）有限公司 | サイクリン依存性キナーゼ９阻害剤としての化合物及びその用途 |
| JP7451765B2 (ja) * | 2020-05-12 | 2024-03-18 | 蘇州阿尓脈生物科技有限公司 | Ｃｄｋ阻害剤としてのピリジンアセトアミド系誘導体、その調製方法及び用途 |
| US20230192703A1 (en) * | 2020-05-12 | 2023-06-22 | Suzhou Alphama Biotechnology Co., Ltd. | Polycyclic amide derivative as CDK9 inhibitor, preparation method therefor and use thereof |
| CN116615248A (zh) | 2020-06-24 | 2023-08-18 | 阿斯利康(英国)有限公司 | 抗体-药物缀合物和cdk9抑制剂的组合 |
| EP4194450A4 (en) | 2020-08-07 | 2024-10-30 | Pharmablock Sciences (Nanjing), Inc. | CDK9 INHIBITOR AND USE THEREOF |
| TWI809330B (zh) * | 2020-11-20 | 2023-07-21 | 大陸商勁方醫藥科技(上海)有限公司 | Cdk9抑制劑的多晶型物及其製法和用途 |
| CN115381823B (zh) * | 2021-05-24 | 2024-11-05 | 石药集团中奇制药技术（石家庄）有限公司 | 一种周期蛋白依赖性激酶9抑制剂的用途 |
| CN115381824B (zh) * | 2021-05-24 | 2024-11-05 | 石药集团中奇制药技术（石家庄）有限公司 | 周期蛋白依赖性激酶9抑制剂的用途 |
| CN117813289A (zh) * | 2021-07-14 | 2024-04-02 | 上海海雁医药科技有限公司 | 吡唑衍生物及其中间体和制备方法 |
| CN115703738B (zh) * | 2021-08-16 | 2024-06-21 | 中国科学院上海药物研究所 | 含2-芳杂环取代的脲类化合物、其制备方法和用途 |
| AU2022419653A1 (en) * | 2021-12-23 | 2024-07-18 | Katholieke Universiteit Leuven | Tetrahydropyrazolopyrimidines and related analogs for inhibiting yap/taz-tead |
| JP2025528223A (ja) | 2022-08-17 | 2025-08-26 | コリア リサーチ インスティテュート オブ ケミカル テクノロジー | Ｃｄｋ２及び／又はｃｄｋ９の抑制又は分解用化合物及びこれらの医薬用途 |
| CN117659022A (zh) * | 2022-09-06 | 2024-03-08 | 苏州阿尔脉生物科技有限公司 | 脲基取代吡啶类化合物、包含其的药物组合物及其医药用途 |
| WO2024220876A1 (en) * | 2023-04-19 | 2024-10-24 | Alcon Inc. | N-substituted c6 cyclyl carboxamide compounds and uses thereof |
| WO2025076115A1 (en) * | 2023-10-02 | 2025-04-10 | Prelude Therapeutics Incorporated | Cdk inhibitors and their use as pharmaceuticals |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008133192A1 (ja) | 2007-04-19 | 2008-11-06 | Takeda Pharmaceutical Company Limited | 縮合イミダゾール化合物およびその用途 |
| ES2539518T3 (es) | 2007-04-24 | 2015-07-01 | Astrazeneca Ab | Inhibidores de proteínas quinasas |
| WO2008129071A1 (en) | 2007-04-24 | 2008-10-30 | Ingenium Pharmaceuticals Gmbh | Inhibitors of protein kinases |
| EP2137166B1 (en) | 2007-04-24 | 2012-05-30 | Ingenium Pharmaceuticals GmbH | 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases |
| JP5566879B2 (ja) | 2007-04-24 | 2014-08-06 | インゲニウム ファーマシューティカルズ ジーエムビーエイチ | プロテインキナーゼの阻害剤 |
| WO2008132138A1 (en) | 2007-04-25 | 2008-11-06 | Ingenium Pharmaceuticals Gmbh | Derivatives of 4,6-disubstituted aminopyrimidines |
| SI2212297T1 (sl) | 2007-10-12 | 2011-09-30 | Ingenium Pharmaceuticals Gmbh | Inhibitorji protein kinaz |
| CN102498107A (zh) | 2009-09-04 | 2012-06-13 | 诺瓦提斯公司 | 作为激酶抑制剂的杂芳基化合物 |
| US20110113038A1 (en) | 2009-11-12 | 2011-05-12 | International Business Machines Corporation | Search term security |
| GB201002911D0 (en) | 2010-02-19 | 2010-04-07 | Medical Res Council | Compound |
| AU2011226073B2 (en) | 2010-03-10 | 2015-05-28 | Astrazeneca Ab | 4-Phenyl pyridine analogues as protein kinase inhibitors. |
| AR081810A1 (es) * | 2010-04-07 | 2012-10-24 | Bayer Cropscience Ag | Piridinilpirazoles biciclicos |
| WO2012066065A1 (en) | 2010-11-17 | 2012-05-24 | Novartis Ag | Phenyl-heteroaryl amine compounds and their uses |
| EP2668162A1 (en) * | 2011-01-28 | 2013-12-04 | Novartis AG | Substituted bi-heteroaryl compounds as cdk9 inhibitors and their uses |
| WO2012101063A1 (en) | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyridine biaryl compounds and their uses |
| WO2012101064A1 (en) * | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyrimidine biaryl compounds as protein kinase inhibitors |
| CN103958518B (zh) | 2011-10-06 | 2017-07-04 | 拜耳知识产权有限责任公司 | 杂环基吡啶基吡唑/杂环基嘧啶基吡唑 |
| MX2015012432A (es) | 2013-03-13 | 2016-02-05 | Abbvie Inc | Inhibidores piridinicos de la cinasa cdk9. |
| CA2901929A1 (en) | 2013-03-13 | 2014-10-02 | Abbvie Inc. | Cdk9 kinase inhibitors |
| US9346813B2 (en) | 2013-03-14 | 2016-05-24 | Abbvie Inc. | Substituted pyrrolo[2,3-d]pyrimindines as CDK9 kinase inhibitors |
| WO2014139328A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors |
-
2016
- 2016-06-27 DK DK16733459.8T patent/DK3313838T3/da active
- 2016-06-27 PE PE2017002874A patent/PE20180530A1/es unknown
- 2016-06-27 ME MEP-2019-138A patent/ME03404B/me unknown
- 2016-06-27 RS RS20190564A patent/RS58712B1/sr unknown
- 2016-06-27 ES ES19165726T patent/ES2902148T3/es active Active
- 2016-06-27 WO PCT/EP2016/064899 patent/WO2017001354A1/en not_active Ceased
- 2016-06-27 CN CN201680029447.9A patent/CN107873028B/zh active Active
- 2016-06-27 AU AU2016286200A patent/AU2016286200B2/en active Active
- 2016-06-27 BR BR122019013677-7A patent/BR122019013677B1/pt active IP Right Grant
- 2016-06-27 PT PT16733459T patent/PT3313838T/pt unknown
- 2016-06-27 US US15/193,826 patent/US9845331B2/en active Active
- 2016-06-27 HU HUE16733459A patent/HUE043440T2/hu unknown
- 2016-06-27 MY MYPI2017705054A patent/MY201673A/en unknown
- 2016-06-27 PL PL19165726T patent/PL3539961T3/pl unknown
- 2016-06-27 TN TNP/2017/000486A patent/TN2017000486A1/en unknown
- 2016-06-27 RS RS20220005A patent/RS62781B1/sr unknown
- 2016-06-27 PT PT191657261T patent/PT3539961T/pt unknown
- 2016-06-27 PL PL16733459T patent/PL3313838T3/pl unknown
- 2016-06-27 MX MX2017016244A patent/MX371034B/es active IP Right Grant
- 2016-06-27 EP EP16733459.8A patent/EP3313838B1/en active Active
- 2016-06-27 CR CR20170596A patent/CR20170596A/es unknown
- 2016-06-27 CR CR20210297A patent/CR20210297A/es unknown
- 2016-06-27 CA CA2989499A patent/CA2989499C/en active Active
- 2016-06-27 SI SI201631427T patent/SI3539961T1/sl unknown
- 2016-06-27 ES ES16733459T patent/ES2728356T3/es active Active
- 2016-06-27 EP EP19165726.1A patent/EP3539961B1/en active Active
- 2016-06-27 HR HRP20211970TT patent/HRP20211970T1/hr unknown
- 2016-06-27 HR HRP20190748TT patent/HRP20190748T1/hr unknown
- 2016-06-27 EA EA201890094A patent/EA035383B1/ru not_active IP Right Cessation
- 2016-06-27 SM SM20220005T patent/SMT202200005T1/it unknown
- 2016-06-27 HU HUE19165726A patent/HUE057343T2/hu unknown
- 2016-06-27 DK DK19165726.1T patent/DK3539961T3/da active
- 2016-06-27 KR KR1020187002262A patent/KR102663113B1/ko active Active
- 2016-06-27 LT LTEP16733459.8T patent/LT3313838T/lt unknown
- 2016-06-27 PH PH1/2017/502334A patent/PH12017502334B1/en unknown
- 2016-06-27 LT LTEP19165726.1T patent/LT3539961T/lt unknown
- 2016-06-27 TR TR2019/09286T patent/TR201909286T4/tr unknown
- 2016-06-27 JP JP2017567737A patent/JP6997627B2/ja active Active
- 2016-06-27 SI SI201630247T patent/SI3313838T1/sl unknown
- 2016-06-27 SM SM20190298T patent/SMT201900298T1/it unknown
- 2016-06-28 AR ARP160101956A patent/AR105179A1/es unknown
- 2016-06-28 TW TW105120362A patent/TWI723028B/zh active
-
2017
- 2017-12-06 US US15/833,277 patent/US10717746B2/en active Active
- 2017-12-12 DO DO2017000295A patent/DOP2017000295A/es unknown
- 2017-12-18 IL IL256393A patent/IL256393B/en unknown
- 2017-12-20 SV SV2017005598A patent/SV2017005598A/es unknown
- 2017-12-21 CL CL2017003306A patent/CL2017003306A1/es unknown
- 2017-12-22 NI NI201700174A patent/NI201700174A/es unknown
- 2017-12-28 CO CONC2017/0013713A patent/CO2017013713A2/es unknown
-
2018
- 2018-01-26 ZA ZA2018/00563A patent/ZA201800563B/en unknown
- 2018-09-25 DO DO2018000207A patent/DOP2018000207A/es unknown
-
2019
- 2019-06-19 CY CY20191100636T patent/CY1122111T1/el unknown
-
2020
- 2020-07-17 US US16/931,786 patent/US11352369B2/en active Active
-
2021
- 2021-12-22 CY CY20211101125T patent/CY1125066T1/el unknown
-
2022
- 2022-04-27 US US17/660,935 patent/US20220340592A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122111T1 (el) | Παραγωγα πολυκυκλικου αμιδιου ως cdk9 αναστολεις | |
| CY1124489T1 (el) | Αναστολεις της hpk1 και μεθοδοι χρησης αυτων | |
| CY1121885T1 (el) | Αντι-ογκικες ενωσεις | |
| AR123996A2 (es) | Compuestos tricíclicos novedosos como agentes antineoplásicos | |
| CY1124476T1 (el) | Egfr αναστολεας, και παρασκευη και εφαρμογη αυτου | |
| CY1124173T1 (el) | Υποκατεστημενες ενωσεις αμινοπουρινης, συνθεσεις αυτων και μεθοδοι θεραπειας με αυτες | |
| AR122786A2 (es) | Inhibidores de kras g12c y métodos para su uso | |
| CY1124798T1 (el) | Υποκατεστημενα παραγωγα καρβονουκλεοζιδιων χρησιμα ως παραγοντες κατα των καρκινων | |
| CY1121195T1 (el) | Παραγωγα τετραϋδροναφθαλενιου που αναστελλουνπρωτεϊνη mcl-1 | |
| CY1121804T1 (el) | Καινοτομες ενωσεις πυριμιδινης και πυριδινης και η χρηση τους | |
| CY1117374T1 (el) | Παραγωγα ιμιδαζοπυριδινης, διαδικασια για την παρασκευη αυτων και θεραπευτικη χρηση αυτων | |
| HK1246645A1 (zh) | 细胞周期蛋白依赖性激酶的抑制剂 | |
| WO2016105528A3 (en) | Inhibitors of cyclin-dependent kinase 7 (cdk7) | |
| CY1120024T1 (el) | Υποκατεστημενοι 2-αζαδικυκλοι και χρηση αυτων ως ρυθμιστες υποδοχεα ορεξινης | |
| CY1125047T1 (el) | Διεργασιες για την παρασκευη ενωσεων τυπου οξαθειαζινης | |
| MX2018001424A (es) | Metodos para preparar 6-(aril o heteroaril)-1,3,5-triazin-2,4-diol es y 6-(aril o heteroaril)-1,3,5-triazin-2,4-diaminas. | |
| CY1117197T1 (el) | Ενωσεις τριαζολοπυριδινης ως αναστολεις της κινασης ριμ | |
| CY1122138T1 (el) | Νεα ενωση και διαδικασια | |
| CY1125082T1 (el) | Υποκατεστημενα τριαζολια και μεθοδοι που σχετιζονται με αυτα | |
| MX391999B (es) | Piridinas y su uso en el tratamiento del cáncer. | |
| CY1123927T1 (el) | Παραγωγο 5-μεθυλ-6-φαινυλ-4,5-διυδρο-2η-πυριδαζιν-3-ονης για τη θεραπεια ογκων του εγκεφαλου | |
| CY1124308T1 (el) | Παραγωγα πυραζολυλαμινοβενζιμιδαζολης ως αναστολεις της jak | |
| MX395659B (es) | Compuestos triciclicos y su uso en el tratamiento del cancer | |
| TH1701007125A (th) | อนุพันธ์พอลิไซคลิกเอไมด์ที่เป็นตัวยับยั้งcdk9 | |
| EA201992557A1 (ru) | Противоопухолевые соединения |